Imipenem or meropenem, what is the best choice for Pseudomonas aeruginosa infections?;Imipénème ou méropénème, quel est le meilleur choix pour les infections à Pseudomonas aeruginosa?

Medecine et Maladies Infectieuses

Volumn 33, Issue 11, 2003, Pages 579-583

  Sinave, C ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Carbapenems; Imipenem; Meropenem; MexA MexB OprM; OprD; Pseudomonas aeruginosa

Indexed keywords

CARBAPENEM DERIVATIVE; IMIPENEM; MEROPENEM; PORIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG TRANSPORT; GENE MUTATION; GRAM NEGATIVE INFECTION; IN VITRO STUDY; LABORATORY; MICROBIOLOGY; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; PSEUDOMONAS AERUGINOSA; REGULATORY MECHANISM; UPREGULATION;

EID: 0345306314     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(03)00242-7     Document Type: Article

References (22)

1. Jones RN, Kirby JT, Beach ML, et al. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide Sentry Antimicrobial Surveillance Program 91997-2000). Diagn Microb Infect Dis 2002;43:239-43.
2. Gossens H. Mystic Program: Summary of European data from 1997 to 2000. Diagn Microb Infect Dis 2001;41:183-9.
3. Mendes C, Turner J. Unit differences in pathogen occurrence from the Mystic Program European database (1997-2000). Diagn Microb Infect Dis 2001;41:191-6.
4. Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial Resistance in European Isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000;19:370-4.
5. Iaconis JP, Pitkin DH, Sheikh W, et al. Comparison of Antimicrobial Activity of Meropenem and Six Other Antimicrobial Against Pseudomonas aeruginosa isolates from North American Studies and Clinical Trials. Clin Infect Dis 1997;24(Suppl 2):S 191-6.
6. Henwood CJ, Livermore DM, James D. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 2001;47:789-99.
7. IIMP-7. Antimicrob Agents Chemother 2002;46:255-8.
8. Livermore DM. Acquired carbapenemases. J Antimicrob Chemother 1997;39:673-6.
9. Woodford N, Palepou M-FI, Babini GS, et al. Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet 1998;353:546-7.
10. Livermore DM. 1995. β-Lactamases in Laboratory and Clinical Resistance. Clin Microb Rev 1995;8:557-84.
11. Bush K, Jacoby AJ, Medeiros AA. A Functional Classification Scheme for β-Lactamases and Its Correlation with Molecular Structure. Antimicrob Agents Chemother 1995;39:1211-33.
12. Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to carbapenms. J Antimicrob Chemther 1995;35:1-5.
13. Livermore DM. Of Pseudomonas, porins, pumps and cabapenems. J Antimicrob Chemother 2001;47:247-50.
14. Perz FJ, Gimeno C, Navarro D, et al. Meropenem penetration through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. Chemother 1996;42:210-4.
15. Epp SF, Köhler T, Plésiat P, et al. C-Terminal Region of Pseudomonas aeruginosa Outer Membrane Porin OprD Modulates Susceptibility to Meropenem. Antimicrob Agents Chemother 2001;45:1780-7.
16. Kölher T, Michea-Hamzehpour M, Epp ST, et al. Carbapenem Activities Against Pseudomonas aeruginosa: Respective Contribution of OprD and Efflux Systems. Antimicrob Agents Chemother 1999;43:424-7.
17. Martinez JL, Baquero F. Mutation Frequencies and Antibiotic Resistance. Antimicrob Agents Chemother 2000;44:1771-7.
18. Carmeli Y, Troillet N, Eliopoulos GM, et al. 1999. Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparaison of Risks Associated with Different Antipseudomonas Agents. Antimicrob Agents Chemother 1999;43:1379-82.
19. Cunha BA. Effective antibiotic-resistance control strategies. Lancet 2001;357:1307-8.
20. Pai H, Kim JW, Kim J, et al. 2001. Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates. Antimicrob Agents Chemother 2001;45:480-4.
21. Courvalin P, Trieu-Cuot P. Minimizing Potential Resistance: The Molecular View. Clin Infect Dis 2001;33(Suppl 3):S138-46.
22. Livermore D, Williams D. Beta-Lactams: Mode of Action and Mechanisms of Bacterial Resistance. In: Lorian V, editor. Antibiotics in Laboratory Medicine. William and Wilkins; 1996. p. 502-78 Table 12.21:544-545.